BAMF
KYMR icon

BI Asset Management Fondsmaeglerselskab’s Kymera Therapeutics KYMR Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,234
Closed -$251K – 934
2024
Q4 		$251K Buy
+6,234
New +$282K ﹤0.01% 684

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's KYMR Position: Q1 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 6,234 shares — an estimated $251K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in KYMR in Q4 2024 and held it in 1 quarter. The position peaked at $251K in Q4 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 6,234 Kymera Therapeutics shares in Q1 2025, an estimated $251K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Kymera Therapeutics in Q4 2024 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Kymera Therapeutics position peaked at $251K in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q1 2025, filed 14 May 2025.